Scarica l'app Stockscreener
8.70
5.23%
-0.48
Dopo l'orario di chiusura:
8.39
-0.31
-3.56%
Hcw Biologics Inc Borsa (HCWB) Ultime notizie
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biol - GuruFocus
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biologics Inc (HCWB) - GuruFocus
HCW Biologics Enters Securities Purchase Agreement - TipRanks
HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy? - Defense World
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - GlobeNewswire
HCW Biologics Closes $5 Million Public Offering - TipRanks
HCW Biologics (HCWB) Launches $5M Follow-On Offering - GuruFocus
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offer - GuruFocus
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offering | HCWB Stock News - GuruFocus
Three layers of uncertainty - The Globe and Mail
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - Yahoo Finance
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Trading Halt for HCW Biologics (HCWB) Due to Volatility | HCWB S - GuruFocus
Trading Resumes for HCW Biologics (HCWB) | HCWB Stock News - GuruFocus
HCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership Talks - Nasdaq
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge - marketscreener.com
HCW Biologics (HCWB) Unveils Innovative Pathway for Enhanced CAR - GuruFocus
HCW Biologics presents novel CAR-T cell enhancer By Investing.com - Investing.com Nigeria
HCW Biologics presents novel CAR-T cell enhancer - Investing.com
HCW Biologics Announces Positive Results of Studies of - GlobeNewswire
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization - TradingView
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed By Investing.com - Investing.com South Africa
Friday’s Insider Moves: Top Buys and Sells in US Stocks Revealed - Investing.com
Prediction: Warren Buffett May Be Shifting Out of His Berkshire Hathaway CEO Role, but He's Not Done Investing - The Globe and Mail
Should You Buy Rivian Stock While It Is Still Below $15? - The Globe and Mail
This Well-Known Toy Company Is Set to Be an Outperformer if the Tariff War Continues - The Globe and Mail
Insider Buying: Gary Winer Acquires Shares of HCW Biologics Inc (HCWB) - GuruFocus
Hcw biologics CEO acquires $2.41 million in stock By Investing.com - Investing.com Nigeria
HCW Biologics Executives and Directors Make Significant Stock Purchases - TradingView
Hcw biologics CEO acquires $2.41 million in stock - Investing.com Australia
HCW Biologics Executives Increase Stake in Company - TradingView
Tariffs, Trump, and Turmoil: ETFs to Escape U.S. Uncertainty - The Globe and Mail
Why Airline Stocks Are Flying Higher Today - The Globe and Mail
With Paychex Near Its 52-Week High, Should Investors Buy It Right Now? - The Globe and Mail
iA Financial Corporation Inc. Announces the Payment of a Dividend on Its Common Shares - The Globe and Mail
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - ADVFN
Is XPeng’s Stock (XPEV) a Better Buy Than Tesla Stock (TSLA)? - The Globe and Mail
As the Market Fluctuates in Response to President Donald Trump's Tariffs, What Stocks Are Safe? - The Globe and Mail
Earnings To Watch: Insperity (NSP) Reports Q1 Results Tomorrow - The Globe and Mail
HCWB stock touches 52-week low at $6.99 amid sharp annual decline - Investing.com Australia
Nasdaq 100 Index Today: QQQ Stock Rallies on Recent Earnings Beats - The Globe and Mail
HCW Biologics (NASDAQ:HCWB) Trading 0.1% Higher – Here’s Why - Defense World
HCW Biologics faces lawsuit over construction contract breach - Investing.com Australia
HCW Biologics faces lawsuit over construction contract breach By Investing.com - Investing.com Canada
This SpaceX Rival Is Soaring on a New Multibillion-Dollar Opportunity. Should You Buy the Stock Now? - The Globe and Mail
HCW Biologics enters key agreements; SEC non-review of filing By Investing.com - Investing.com South Africa
HCW Biologics enters key agreements; SEC non-review of filing - Investing.com
HCWB stock touches 52-week low at $8.04 amid market challenges By Investing.com - Investing.com South Africa
HCWB stock touches 52-week low at $8.04 amid market challenges - Investing.com Canada
1.52%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):